Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Economy & Forex

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

New drugs contribute to AbbVie's upbeat 2020 view; shares hit year-high

share with twitter share with LinkedIn share with facebook
02/07/2020 | 12:20pm EDT
FILE PHOTO: A screen displays the share price for drugmaker AbbVie on the floor of the New York Stock Exchange

AbbVie Inc on Friday forecast full-year earnings well above Wall Street estimates, as the U.S. drugmaker looks to new treatments and its pending acquisition of Allergan Plc to drive growth beyond 2023, when its cash cow Humira loses patent protection.

AbbVie said it expects 2020 adjusted earnings of $9.61 to $9.71 per share, above analysts' estimates of $9.48. Its shares rose 5.7% to $92.19, hitting their highest level in a year.

The profit forecast excludes any impact from the pending $63 billion Allergan deal, which is expected to close in the current quarter.

The company is eyeing expanded approvals for its new psoriasis drug Skyrizi and rheumatoid arthritis treatment Rinvoq, both of which AbbVie said have had "strong" launches.

AbbVie forecast that the two drugs will bring in combined revenue of about $1.70 billion in 2020, still less than 9% of expected Humira sales, as it maintains its position as the world's top-selling prescription medicine.

Investors have long fretted about the company's dependence on Humira.

AbbVie is hoping to maintain its leadership position in the $70 billion global immunology market dominated by Humira, which treats both rheumatoid arthritis and psoriasis, as well as several related autoimmune conditions.

"Together, we expect Skyrizi and Rinvoq to have full coverage across the major disease areas for which Humira is currently approved, plus new areas, such as atopic dermatitis," AbbVie President Michael Severino said on a conference call.

AbbVie is also counting on the addition of wrinkle treatment Botox from Allergan, and other products in development to cushion the expected revenue drop after Humira loses U.S. patent protection.

Meanwhile Humira, despite stiff competition, had fourth-quarter sales of $4.92 billion, exceeding analysts' expectations of $4.85 billion, according to Refinitiv data.

Skyrizi brought in sales of $216 million, topping estimates of about $142 million. Rinvoq had sales of $33 million in its first full quarter on the market.

"While AbbVie is seeking to shine light on its early stage pipeline, we anticipate the performance of the stock will be heavily tied to ongoing Skyrizi and Rinvoq rollouts," said Citi analyst Andrew Baum.

He also expects investors to focus on delivery of promised savings from the Allergan deal.

Excluding items, AbbVie earned $2.21 per share in the fourth quarter, edging past expectations by 2 cents.

Revenue rose 4.8% to $8.70 billion, in line with the average analysts' estimate of $8.69 billion.

(Reporting by Manas Mishra and Tamara Mathias in Bengaluru, Carl O'Donnell in New York; Editing by Arun Koyyur and Bill Berkrot)

By Tamara Mathias and Manas Mishra


Stocks mentioned in the article
ChangeLast1st jan.
BYD COMPANY LIMITED 5.45% 149.1 End-of-day quote.283.78%
NEXT PLC 0.82% 6134 Delayed Quote.-13.22%
THE GLOBAL LTD. 2.65% 232 End-of-day quote.-50.74%
WORLD CO., LTD. -2.24% 1353 End-of-day quote.-49.72%
share with twitter share with LinkedIn share with facebook
Latest news "Economy & Forex"
12:59pWALL STREET STOCK EXCHANGE : S&P 500, Dow sink to late-Sept lows on virus woes
RE
12:50pGold slides on dollar rally as U.S. stimulus remains elusive
RE
12:00pBoeing deepens job cuts as profit slumps on 737 MAX, COVID crises
RE
11:36aWorld Bank sanctions Chinese engineering firms in Zambian power project
RE
11:16aNEWS HIGHLIGHTS : Top Global Markets News of the Day
DJ
11:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
11:16aNEWS HIGHLIGHTS : Top Financial Services News of the Day
DJ
11:10aGhana government in talks to takeover AirtelTigo shares
RE
10:52aGE's shares soar as earnings recover from pandemic lows
RE
10:52aZambia wins deferral on China Development Bank loan repayments
RE
Latest news "Economy & Forex"